Sarah Reade

Phase I and Pharmacodynamic Trial of the DNA Methyltransferase Inhibitor Decitabine and Carboplatin in Solid Tumors

Kim Appleton, Helen Mackay, Ian Judson et al. · Journal of Clinical Oncology · 2007 · 229 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors

Richard D. Baird, Jos Kitzen, Paul A. Clarke et al. · Molecular Cancer Therapeutics · 2009 · 47 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Phase I pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of a small molecule inhibitor of Poly ADP-Ribose Polymerase (PARP), KU-0059436 (Ku) in patients (p) with advanced tumours

Peter C.C. Fong, James Spicer, Sarah Reade et al. · Journal of Clinical Oncology · 2006 · 35 citations

Medicine, Oncology, Pharmacology +16

Phase I/II study of DHA–paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours

Mark Harries, Anne O’Donnell, Michelle Scurr et al. · British Journal of Cancer · 2004 · 26 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1–5 of a 3-weekly cycle in patients with advanced solid tumours

Maja J.A. de Jonge, Stan B. Kaye, Jaap Verweij et al. · British Journal of Cancer · 2004 · 19 citations · Full text

Medicine, Oncology, Pharmacology +14